Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 1
2013 1
2014 2
2015 3
2016 5
2017 6
2018 5
2019 8
2020 8
2021 6
2022 8
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Cemiplimab-Induced Alopecia Areata.
Piraccini BM, Comito F, Melotti B, Stanganelli I, Medri M, Savoia F. Piraccini BM, et al. Among authors: melotti b. Int J Trichology. 2023 Mar-Apr;15(2):77-78. doi: 10.4103/ijt.ijt_107_21. Epub 2023 Jul 28. Int J Trichology. 2023. PMID: 37701555 Free PMC article. No abstract available.
Early palliative care and quality of life of advanced cancer patients-a multicenter randomized clinical trial.
Franciosi V, Maglietta G, Degli Esposti C, Caruso G, Cavanna L, Bertè R, Bacchini G, Bocchi L, Piva E, Monfredo M, Scafuri V, Di Cesare P, Melotti B, Sequino M, Rimanti A, Binovi C, Ghisoni F, Caminiti C. Franciosi V, et al. Among authors: melotti b. Ann Palliat Med. 2019 Sep;8(4):381-389. doi: 10.21037/apm.2019.02.07. Epub 2019 Mar 14. Ann Palliat Med. 2019. PMID: 30943735 Free article. Clinical Trial.
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. John T, et al. Among authors: melotti b. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. J Thorac Oncol. 2023. PMID: 37236398 Free article. Clinical Trial.
Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?
Dika E, Lambertini M, Pellegrini C, Veronesi G, Melotti B, Riefolo M, Sperandi F, Patrizi A, Ricci C, Mussi M, Fargnoli MC. Dika E, et al. Among authors: melotti b. J Clin Med. 2021 Jan 28;10(3):478. doi: 10.3390/jcm10030478. J Clin Med. 2021. PMID: 33525348 Free PMC article. Review.
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience.
De Giglio A, Grandinetti V, Aprile M, Borelli G, Campus A, Croci Chiocchini AL, Busutti M, Vischini G, Di Federico A, Sperandi F, Melotti B, Ardizzoni A, La Manna G, Gelsomino F. De Giglio A, et al. Among authors: melotti b. Lung Cancer. 2022 Dec;174:91-96. doi: 10.1016/j.lungcan.2022.10.007. Epub 2022 Nov 2. Lung Cancer. 2022. PMID: 36356493
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, Antiga E, Maglie R, Cozzani E, Parodi A, Gasparini G, Sollena P, De Simone C, Caproni M, Pisano L, Fattore D, Balestri R, Sena P, Vezzoli P, Teoli M, Ardigò M, Vassallo C, Michelerio A, Satta RR, Dika E, Melotti B, Ribero S, Quaglino P. Merli M, et al. Among authors: melotti b. Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37547602 Free PMC article.
62 results